tbuckley/cabot-search huggingface dataset:
Primula Dermatitis
Authors: A. Rook, H. T. H. Wilson
Journal: BMJ (1965)

Chromatographic separation methods of all kinds-paper, column, and gas chromatography-have made a tremendous impact in this field, as they have in all other fields of analytical and preparative chemistry.Used in combination with various methods for determining the isotope content of tracers, they dominate the field.For determination of 14C in the form of 14CO2 the low background anticoincidence counter has found COOH COOH CHO C-OP COOH / HCOH CH2 Co HO, COOH COOH phosphoenol IH HO¢H pyruvic 0.
Vaginismus.
Authors: E Stanley
Journal: BMJ (1981)

<b>Objective:</b> To use quantitative myocardial contrast echocardiography (MCE) and strain rate imaging (SRI) to assess the role of microvascular disease in subclinical diabetic cardiomyopathy. <b>Methods:</b> Stress MCE and SRI were performed in 48 patients (22 with type II diabetes mellitus (DM) and 26 controls), all with normal left ventricular systolic function and no obstructive coronary disease by quantitative coronary angiography. Real-time MCE was acquired in three apical views at rest and after combined dipyridamole–exercise stress. Myocardial blood flow (MBF) was quantified in the 10 mid- and apical cardiac segments at rest and after stress. Resting peak systolic strain rate (SR) and peak systolic strain (ε) were calculated in the same 10 myocardial segments. <b>Results:</b> The DM and control groups were matched for age, sex and other risk factors, including hypertension. The DM group had higher body mass index and left ventricular mass index. Quantitative SRI analysis was possible in all patients and quantitative MCE in 46 (96%). The mean ε, SR and MBF reserve were all significantly lower in the DM group than in controls, with diabetes the only independent predictor of each parameter. No correlation was seen between MBF and SR (r = −0.01, p = 0.54) or between MBF and ε (r = −0.20, p = 0.20). <b>Conclusions:</b> Quantitative MCE shows that patients with diabetes but no evidence of obstructive coronary artery disease have impaired MBF reserve, but abnormal transmural flow and subclinical longitudinal myocardial dysfunction are not related.
THURSDAY 22ND SEPTEMBER
Authors: N Nikiteas, M Keighley, Elizabeth Hospital, J Smithson, G Radford-Smith, D Jewell, Inflammatory Bowel, Disease Thompson, A Wakefield, Thromboxane Collins, A Forbes, Colitis Ad, Millar Dr Blake, M Peeters, Y Ghoos, B Geypens, M Hide, P Rutgeerts, Iavis Spl, Kettlewell Mgw, Mortensen Nm, Jewall John, J Lee2, D Ford3, D Easton3, Svh Hodgson', J Lennard-Jones2, Cg Div Med, Mol Geics
Journal: Gut (1994)

We decided to audit the results of sphincter repair because of a result of a change of surgical policy: All patients had a complete sphincter defect and all patients had been followed up for more than 6 months.Sphincter repair was performed in 6 men: 3 posterior defects associated with fistula operations and 3 anterior defects from perineal trauma associated with urethral injury and pelvic fractures.Only one of the 3 posterior repairs was associated with any residual minor incontinence, which was cured by graciloplasty.All of the anterior defects had required a stoma at the time of injury; despite this and complete reconstruction of the anterior rectum, only one patient is continent.Eighteen women had sphincter repairs, one was a lateral repair from previous fistula surgery with a good result.The remaining 17 defects were anterior reconstructions and included anterior levatorplasty, Zplasty as well as sphincter repair.Only 2 had a covering stoma (both delayed for 48 hours).Seven patients had persistent incontinence (major 3, minor 4) and two have had successful repeat repairs.Factors in this female group associated with persistent incontinence were age over 50 years (3 of 4), obesity (2 of 3), post-operative sepsis (3 of 4) and gross perineal descent (5 of 8).These results raise the role of a stoma, particularly in obese and elderly women having sphincter repair.
Correction: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner
Authors: Dipti Thakkar, Shalini Paliwal, Bhushan Dharmadhikari, Siyu Guan, Lillian Liu, Shreya Kar, Nikhil Tulsian, Joshua Gruber, Leah Dimascio, Konrad Pasz- Kiewicz, Piers Ingram, Jerome Boyd-Kirkup
Journal: Journal for ImmunoTherapy of Cancer (2022)

Correction: Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
Authors: Angela M. Araujo, Andrea Abaurrea, Peio Azcoaga, Joanna I. López-Velazco, Sara Manzano, Javier Rodriguez, Ricardo Rezola, Leire Egia-Mendikute, Fátima Valdés-Mora, Juana M. Flores, Liam Jenkins, Laura Pulido, Iñaki Osorio-Querejeta, Patricia Fernández-Nogueira, Nicola Ferrari, Cristina Viera, Natalia Martín-Martín, Alexandar Tzankov, Serenella Eppenberger-Castori, Isabel Alvarez-Lopez, Ander Urruticoechea, Paloma Bragado, Nicholas Coleman, Asís Palazón, Arkaitz Carracedo, David Gallego-Ortega, Fernando Calvo, Clare M. Isacke, María M. Caffarel, Charles H. Lawrie
Journal: Journal of Clinical Investigation (2022)

The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.
Immunologically Specific Antigens in Leukemic Tissues
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRANCE
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Spector of ground war overshadows Desert Storm medical, peace efforts
Authors: P. Gunby
Journal: JAMA (1991)

HOPES for peace, but a possible ground war, occupy US military medical planners as February draws to a close. However, this does not mean that fliers who have been waging the Desert Storm air war for 6 weeks are being overlooked. Monte B. Miller, MD, the three-star (lieutenant) general who is surgeon general of the US Air Force, emphasizes that there is a flight surgeon with every one of the squadrons that are flying against Iraqi forces. "There is no laboratory test to determine aircrew fatigue," Miller points out. "But our flight surgeons are living and working right there beside them, and can spot the flier who is becoming overstressed and needs to be grounded for a while to rest." Navy flight surgeons similarly are monitoring carrier-based and US Marine Corps fliers, as are Army physicians who are looking after helicopter aircrews. In addition to missions flown from bases or
Evaluating therapeutic bladder cancer trial disparities in race/ethnicity.
Authors: Ishaan Iyer, Sylvia Zhang, Hala Borno
Journal: Journal of Clinical Oncology (2022)

446 Background: Racial clinical trial disparities in bladder cancer outcomes remains a critical problem in the United States. This study sought to examine representation by race and sex among therapeutic bladder cancer clinical trials that informs the standard of care in bladder cancer management. Methods: Published clinical trial data that inform clinical management were identified from the National Comprehensive Cancer Network guidelines and by clinician input from 2009 to 2021. The characteristics of participants, including sex and race, were collected. Clinical trials were categorized by clinical setting: metastatic bladder cancer (MBC), muscle invasive bladder cancer (MIBC), and non-muscle invasive (NMIBC). Bladder cancer incidence by race were collected from the Surveillance, Epidemiology, and End Results (SEER) Program. SEER incidence data by race was compared to the racial/ethnic breakdown of bladder cancer clinical trial participants and evaluated using hypothesis testing (chi-square). Results: A total of 28 clinical trials were assessed, with a pooled sample of 8003 participants. race was reported for 1786 participants. A total of 17 clinical trials did not report race. The population data from SEER details bladder cancer distributions as 89.52% White, 5.80% Black, 0.33% American Indian/Alaska Native, and 4.36% Asian or Pacific Islander. Chi-square analysis demonstrated significant differences in racial representation for MBC (p&lt; 0.0001) and NMIBC (p=0.0423) settings. No significant differences were observed in the MIBC (p= 0.1954) setting. Conclusions: This study observed that the distributions of race in MBC and NMIBC clinical trials are different from that of the population affected by bladder cancer. It is imperative for therapeutic cancer clinical trials to achieve adequate representation to ensure standard of care therapies in bladder cancer management benefits all.[Table: see text]
Author Correction: EMPReSS: standardized phenotype screens for functional annotation of the mouse genome
Authors: Marc Janier, Mohammed Almadjub, Olivier Beuf, Claire Billotey, Radu Bolbos, Laurence Canaple, Emmanuel Chereul, Denis Grenier, Bassem Hiba, Christophe Odet, Jean-Baptiste Langlois, Carole Lartizien, Luc Magnier, Wilfried Ma, Tarik Zouagui, Mark Lathrop, Ivo Gut, Anne Puech, Yann Hérault, Véronique Blanquet, Veronique Brault, Jacques Samarut, Denise Aubert, Michela Plateroti, Nadia Rosenthal, Mumna Al Banchaabouchi, Janice Carter, Olga Ermakova, Karin Gale, Jose Gonzalez, Emerald Perlas, Jeanette Rientjes, Annett Spanner, Anne-Cecile Trillat, Glauco Tocchini-Valentini, Silvia Mandillo, Elisabetta Golini, Daniela Marazziti, Giancarlo Deidda, Nicoletta Rossi, Rafaele Matteoni, Marcello Raspa, Ferdinando Scavizzi, Mariano Barbacid, Marivi Victoria Campuzano, Pierre Dubus, Lucía Perez Gallego, Carmen Guerra González, Rudi Balling, Ursula Frischmann, Hansjörg Hauser, Andreas Lengeling, Werner Müller, Bastian Pasche, Martin Hrabé de Angelis, Wolfgang Wurst, Koichiro Abe, Johannes Beckers, Dirk H. Busch, Claudia Dalke, Valerie Gailus Durner, Ralf Elvert, Tobias J. Franz, Helmut Fuchs, Jochen Graw, Sabine M. Hölter, Thilo Jakob, Svetoslav Kalaydjiev, Magdalena Kallnik, Martina Klempt, Martin Klingenspor, Thomas Klopstock, Christoph Lengger, Leticia Quintanilla Martinez, Vera Pedersen, Oliver Puk, Ilka Schneider, Daniela Vogt Weisenhorn, Sabine Wagner, Eckhard Wolf, Pierre Chambon, Johan Auwerx, Dalila Ali-Hadji, Marie-France Champy, Nelly Frossard, Jean-Jacques Helwig, Manuel Mark, Laurent Monassier, Maria Cristina Antal, Mariette Barthelmebs, Agnes Bloch-Zupan, Andre Constantinesco, Pascal Doll, Lahcen El Fertak, Françoise Gofflot, Laurent Juillard, Wojciech Krezel, Hamid Meziane, Abdel-Mouttalib Ouagazzal, Françoise Pons, Raymond Romand, Mohammed Selloum, Tania Sorg, Marius Teletin, Laurent Vasseur, Olivia Wendling, Philip Avner, Sophie Chantalat, Urban Lendahl, Johannes Wilbertz, Kay Davies, Peter Oliver, Michael Cheeseman, Emma Coghill, Roger Cox, Liz Bentley, Simon Ferguson, Hilary Gates, Georgios Gkoutos, Eain Green, John Hancock, Tertius Hough, Robert Johnson, Heena Lad, Ann-Marie Mallon, Pat Nolan, Andy Parker, Julie Quarterman, Adrian Smith, Mandy Studley, Aadya Shukla, Hilda Tateossian, Valter Tucci, Joseph Weekes, Ian Jackson, Sally Cross, Duncan Davidson, Alan Hart, Angus Murray, Anton Berns, Marco Breuer, Evert van Garderen, Jos Jonkers, Ji Ying Song, Martin van der Valk, Ludwig Neyses, Elizabeth Cartwright, Delvac Oceandy, Michael Emerson, Walter Wahli, Maria Belen Delgado, Batrice Desvergne, Liliane Michalik, Elodie Bedu, Denis Duboule, Marie Kmita, Jozsef Zakany, Francois Spitz, Allan Bradley, Madhuri Warren
Journal: Nature Genetics (2022)
Financial toxicity and its effect on screening for prostate and colon cancer.
Authors: Michael Joseph Herriges, Rachel Shenhav-Goldberg, Juliet Irene Peck, Oleg Shapiro, Joseph M Jacob, Alina Basnet, Gennady Bratslavsky, Hanan Goldberg
Journal: Journal of Clinical Oncology (2022)

21 Background: The term ‘financial toxicity’ or ‘hardship’ is used to describe the financial problems patients experience due to high out-of-pocket costs for their healthcare. Financial toxicity in the context of cancer treatment is an area of recent study due to the significant costs associated with these treatments, but little is known about the effect of financial toxicity on cancer prevention. We examined the effects of financial toxicity on the utilization of screening tests for prevalent cancers, including prostate and colon cancer, using a US nationally representative survey-based data source. We hypothesized that patients with more financial hardship would show an association with decreased prevalence of prostate and colon cancer screening. Methods: This cross-sectional survey-based US study included men and women aged 18+ from the National Health Interview Survey (NHIS) database from January – December 2018. A financial hardship score between 0 and 1 was formulated by summarizing the responses from ten financial toxicity questions including if in the past 12 months one was unable to afford prescription medication or healthcare; or if one had to skip or take less medicine to save money. A higher score was associated with a worse financial hardship score. The primary outcomes of the study were self-reported occurrence of PSA blood testing for prostate cancer screening, and occurrence of colonoscopy for colon cancer screening. Results: As shown in table, a higher financial hardship score was associated with a decreased odds ratio for having a PSA test of 0.916 (95% CI 0.867-0.967, p=0.002) and colonoscopy of 0.969 (95% CI 0.941-0.998, p=0.039). Conclusions: Worse financial hardship is associated with a decreased probability of having PSA or colonoscopy screening tests. Awareness of this specific toxicity needs to be raised, examining the association of financial toxicity and screening of prostate, colon, and other additional cancers. [Table: see text]
Medical education programs sponsored by government agencies
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A TEST FOR "CHRISTIAN SCIENTISTS."
Journal: JAMA (1900)

A Detroit physician has been applying the<i>argumentum ad hominem</i>to the "Christian Scientists," by proposing to give them hypodermic injections of substances the effects of which on the system are known, and letting them try to nullify them by faith. This is a perfectly fair proposition, and if their faith really amounted to anything they ought to be willing to submit to such experimentation, but, so far, none have responded to the challenge. Such a test as this even when only proposed ought to demonstrate the fraud to the very simplest minded, and yet the Eddyites and Dowieites will continue to flourish. If language was given, as Talleyrand said, for the purpose of concealing thoughts, reason must have been given some men for the purpose of making fools of themselves; at least that would explain "Christian Science" and its vagaries. If, as has been remarked by the<i>Detroit Free</i>
Arquivos de Neuro-Psiquiatria, São Paulo
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).
Authors: Dimitrios Makrakis, Rafee Talukder, Scott Dawsey, Lucia Carril, Tyler F. Stewart, Rafael Morales-Barrera, Joseph J. Park, Claudia Angela Maria Fulgenzi, Jure Murgic, Naomi Vather-Wu, Ivan de Kouchkovsky, Michael Edward Devitt, Giuseppe Di Lorenzo, Kavita Gupta, Nishita Tripathi, Roubini Zakopoulou, Abhishek Tripathi, Eric Lu, Petros Grivas, Ali Raza Khaki
Journal: Journal of Clinical Oncology (2022)

505 Background: Current standard therapy for most pts with aUC is first-line (1L) platinum-based chemotherapy followed by ICI maintenance (or 2L if progression). Shorter time on 1L or between therapy lines may be a surrogate of more aggressive disease and poor outcome, but its prognostic role in ICI response is unclear. We hypothesized that shorter time until start of 2L ICI would be associated with worse outcomes in aUC. Methods: We performed a retrospective multi-institution cohort study in pts with aUC treated with 1L platinum-based chemotherapy, who later received 2L ICI. Pts receiving maintenance ICI were excluded. We calculated the time from start of 1L platinum chemotherapy to start of 2L ICI, dichotomizing the exposure into ≤6 months and &gt;6 months. We compared overall response rate (ORR) to 2L ICI, progression-free survival (PFS) and overall survival (OS) from the start of 2L ICI between the two populations. ORR was compared among groups using multivariable logistic regression and PFS, OS using cox regression. Analysis was adjusted for calculated Bellmunt score. Results: From a total of 1283 pts, 462 received 1L platinum chemotherapy; among those, 350 received 2L ICI. After exclusions, 270, 269 and 260 pts were included in the ORR, PFS and OS analyses, respectively. Median age was 70 years, 78% men, 75% White, 74% with pure urothelial histology, 21% upper tract, 60% received cisplatin in 1L. Pts with time to 2L ICI ≤6 months had significantly higher Bellmunt scores (32% vs 22% score=2, 9% vs 3% score=3). ORR and PFS were comparable between pts with ≤ and &gt;6 months to 2L ICI. However, OS was significantly longer for pts with &gt;6 months to 2L ICI (median [m]OS 13 vs 7 months, p=0.002), (Table). Conclusions: Among pts with aUC treated with 2L ICI, time to 2L ICI ≤6 months from 1L platinum based chemotherapy was associated with similar ORR and PFS but shorter OS. Limitations include retrospective nature, patient selection, confounding factors. More studies are needed on the impact of platinum resistance in pts with aUC treated with ICIs.[Table: see text]